The ability of King’s clinical staging and Milano-Torino (MiToS) functional staging in the prediction of amyotrophic lateral sclerosis (ALS) progression: A meta-analysis study
Main Article Content
Keywords
Amyotrophic lateral sclerosis (ALS), staging systems, King’s staging, Milano-Torino (MiToS) staging, meta-analysis.
Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by functional connectivity alterations in both motor and extra-motor brain regions. Assessing clinical progression in amyotrophic lateral sclerosis (ALS) remains a challenge. Our objective was to assess the effectiveness, utility, precision, and validity of the King's staging system and the Milano-Torino Staging (MiToS) system by comparing them in terms of charting disease progression within a clinical setting.
References
1. Knibb JA, Keren N, Kulka A, Leigh PN, Martin S, Shaw CE, et al. A clinical tool for predicting survival in ALS. J Neurol Neurosurg Psychiatry. 2016;87(12):1361–7.
2. Bersano E, Sarnelli MF, Solara V, Iazzolino B, Peotta L, De Marchi F, et al. Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study. Amyotroph Lateral Scler Front Degener. 2020;21(5–6):373–9.
3. Agosta F, Ferraro PM, Riva N, Spinelli EG, Chio A, Canu E, et al. Structural brain correlates of cognitive and behavioral impairment in MND. Hum Brain Mapp. 2016;37(4):1614–26.
4. Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH-M, Butt D, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 2006;253:1642–3.
5. Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph lateral Scler. 2009;10(5–6):310–23.
6. Sinaki M, Mulder DW. Rehabilitation techniques for patients with amyotrophic lateral sclerosis. In: Mayo Clinic Proceedings. 1978. p. 173–8.
7. Hillel AD, Miller RM, Yorkston K, McDonald E, Norris FH, Konikow N. Amyotrophic lateral sclerosis severity scale. Neuroepidemiology. 1989;8(3):142–50.
8. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 1998;55(4):526–8.
9. Lacomblez L, Bensimon G, Douillet P, Doppler V, Salachas F, Meininger V. Xaliproden in amyotrophic lateral sclerosis: early clinical trials. Amyotroph Lateral Scler Other Mot Neuron Disord. 2004;5(2):99–106.
10. Puentes F, Topping J, Kuhle J, van der Star BJ, Douiri A, Giovannoni G, et al. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(3):274–8.
11. Oh J, An JW, Oh S-I, Oh KW, Kim JA, Lee JS, et al. Socioeconomic costs of amyotrophic lateral sclerosis according to staging system. Amyotroph Lateral Scler Front Degener. 2015;16(3–4):202–8.
12. Balendra R, Jones A, Jivraj N, Steen IN, Young CA, Shaw PJ, et al. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg Psychiatry. 2015;86(1):45–9.
13. Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265–7.
14. Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci. 2008;275(1–2):69–73.
15. Shamshiri H, Fatehi F, Davoudi F, Mir E, Pourmirza B, Abolfazli R, et al. Amyotrophic lateral sclerosis progression: Iran-ALS clinical registry, a multicentre study. Amyotroph Lateral Scler Front Degener. 2015;16(7–8):506–11.
16. Franchignoni F, Mandrioli J, Giordano A, Ferro S, Group E. A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements. Amyotroph Lateral Scler Front Degener. 2015;16(5–6):331–7.
17. Franchignoni F, Mora G, Giordano A, Volanti P, Chiò A. Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis. J Neurol Neurosurg Psychiatry. 2013;84(12):1340–5.
18. Tortelli R, Copetti M, Panza F, Cortese R, Capozzo R, D’Errico E, et al. Time to generalisation as a predictor of prognosis in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2016;87(6):678–9.
19. Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135(3):847–52.
20. Chiò A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(1):38–44.
21. Fang T, Al Khleifat A, Stahl DR, Lazo La Torre C, Murphy C, LicalS U-M, et al. Comparison of the King’s and MiToS staging systems for ALS. Amyotroph lateral Scler Front Degener. 2017;18(3–4):227–32.
22. Al-Chalabi A, Chiò A, Merrill C, Oster G, Bornheimer R, Agnese W, et al. Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19. J Neurol Neurosurg Psychiatry. 2021;92(2):165–71.
23. Liberati M, Tetzlaff J, Altman DG. group tP. Preferred Reporting items for systematic reviews and meta analyses: THE PRISMA statement. Plos Med. 2009;6(7):1–6.
24. NEWCASTLE-OTTAWA QUALITY ASSESSMENT SCALE CASE CONTROL STUDIES.
25. Abdul Aziz NA, Toh T-H, Loh E-C, Capelle DP, Goh K-J, Abdul Latif L, et al. The utility of ALS staging systems in a multi-ethnic patient cohort. Amyotroph Lateral Scler Front Degener. 2021;22(5–6):341–9.
26. Ferraro D. Amyotrophic lateral sclerosis: a comparison of two staging systems in a 1364 population-based study. Eur W Neurol. 2016;23(1426–32):1365.
27. Luna J, Couratier P, Lahmadi S, Lautrette G, Fontana A, Tortelli R, et al. Comparison of the ability of the King’s and MiToS staging systems to predict disease progression and survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2021;22(7–8):478–85.
28. Romano A, Lopez ET, Liparoti M, Polverino A, Minino R, Trojsi F, et al. The progressive loss of brain network fingerprints in Amyotrophic Lateral Sclerosis predicts clinical impairment. NeuroImage Clin. 2022;35:103095.
29. Thakore NJ, Lapin BR, Kinzy TG, Pioro EP. Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach. Amyotroph Lateral Scler Front Degener. 2018;19(7–8):483–94.
30. Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol [Internet]. 2018 May 1 [cited 2023 Sep 6];17(5):416–22. Available from: http://www.thelancet.com/article/S1474442218300541/fulltext
31. De Jongh AD, Van Eijk RPA, Van Den Berg LH. Evidence for a multimodal effect of riluzole in patients with ALS? J Neurol Neurosurg Psychiatry. 2019;1–2.
32. Tramacere I, Dalla Bella E, Chiò A, Mora G, Filippini G, Lauria G. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(11):1180–5.
33. Chiò A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry [Internet]. 2015 Jan 1 [cited 2023 Sep 6];86(1):38–44. Available from: https://jnnp.bmj.com/content/86/1/38
34. Jones AR, Jivraj N, Balendra R, Murphy C, Kelly J, Thornhill M, et al. Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2014;15(3–4):285–91.
35. Balendra R, Al Khleifat A, Fang T, Al-Chalabi A. A standard operating procedure for King’s ALS clinical staging. Amyotroph Lateral Scler Front Degener. 2019;20(3–4):159–64.
2. Bersano E, Sarnelli MF, Solara V, Iazzolino B, Peotta L, De Marchi F, et al. Decline of cognitive and behavioral functions in amyotrophic lateral sclerosis: a longitudinal study. Amyotroph Lateral Scler Front Degener. 2020;21(5–6):373–9.
3. Agosta F, Ferraro PM, Riva N, Spinelli EG, Chio A, Canu E, et al. Structural brain correlates of cognitive and behavioral impairment in MND. Hum Brain Mapp. 2016;37(4):1614–26.
4. Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH-M, Butt D, et al. Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol. 2006;253:1642–3.
5. Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al. Prognostic factors in ALS: a critical review. Amyotroph lateral Scler. 2009;10(5–6):310–23.
6. Sinaki M, Mulder DW. Rehabilitation techniques for patients with amyotrophic lateral sclerosis. In: Mayo Clinic Proceedings. 1978. p. 173–8.
7. Hillel AD, Miller RM, Yorkston K, McDonald E, Norris FH, Konikow N. Amyotrophic lateral sclerosis severity scale. Neuroepidemiology. 1989;8(3):142–50.
8. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 1998;55(4):526–8.
9. Lacomblez L, Bensimon G, Douillet P, Doppler V, Salachas F, Meininger V. Xaliproden in amyotrophic lateral sclerosis: early clinical trials. Amyotroph Lateral Scler Other Mot Neuron Disord. 2004;5(2):99–106.
10. Puentes F, Topping J, Kuhle J, van der Star BJ, Douiri A, Giovannoni G, et al. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(3):274–8.
11. Oh J, An JW, Oh S-I, Oh KW, Kim JA, Lee JS, et al. Socioeconomic costs of amyotrophic lateral sclerosis according to staging system. Amyotroph Lateral Scler Front Degener. 2015;16(3–4):202–8.
12. Balendra R, Jones A, Jivraj N, Steen IN, Young CA, Shaw PJ, et al. Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials. J Neurol Neurosurg Psychiatry. 2015;86(1):45–9.
13. Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265–7.
14. Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci. 2008;275(1–2):69–73.
15. Shamshiri H, Fatehi F, Davoudi F, Mir E, Pourmirza B, Abolfazli R, et al. Amyotrophic lateral sclerosis progression: Iran-ALS clinical registry, a multicentre study. Amyotroph Lateral Scler Front Degener. 2015;16(7–8):506–11.
16. Franchignoni F, Mandrioli J, Giordano A, Ferro S, Group E. A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements. Amyotroph Lateral Scler Front Degener. 2015;16(5–6):331–7.
17. Franchignoni F, Mora G, Giordano A, Volanti P, Chiò A. Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis. J Neurol Neurosurg Psychiatry. 2013;84(12):1340–5.
18. Tortelli R, Copetti M, Panza F, Cortese R, Capozzo R, D’Errico E, et al. Time to generalisation as a predictor of prognosis in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2016;87(6):678–9.
19. Roche JC, Rojas-Garcia R, Scott KM, Scotton W, Ellis CE, Burman R, et al. A proposed staging system for amyotrophic lateral sclerosis. Brain. 2012;135(3):847–52.
20. Chiò A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(1):38–44.
21. Fang T, Al Khleifat A, Stahl DR, Lazo La Torre C, Murphy C, LicalS U-M, et al. Comparison of the King’s and MiToS staging systems for ALS. Amyotroph lateral Scler Front Degener. 2017;18(3–4):227–32.
22. Al-Chalabi A, Chiò A, Merrill C, Oster G, Bornheimer R, Agnese W, et al. Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19. J Neurol Neurosurg Psychiatry. 2021;92(2):165–71.
23. Liberati M, Tetzlaff J, Altman DG. group tP. Preferred Reporting items for systematic reviews and meta analyses: THE PRISMA statement. Plos Med. 2009;6(7):1–6.
24. NEWCASTLE-OTTAWA QUALITY ASSESSMENT SCALE CASE CONTROL STUDIES.
25. Abdul Aziz NA, Toh T-H, Loh E-C, Capelle DP, Goh K-J, Abdul Latif L, et al. The utility of ALS staging systems in a multi-ethnic patient cohort. Amyotroph Lateral Scler Front Degener. 2021;22(5–6):341–9.
26. Ferraro D. Amyotrophic lateral sclerosis: a comparison of two staging systems in a 1364 population-based study. Eur W Neurol. 2016;23(1426–32):1365.
27. Luna J, Couratier P, Lahmadi S, Lautrette G, Fontana A, Tortelli R, et al. Comparison of the ability of the King’s and MiToS staging systems to predict disease progression and survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2021;22(7–8):478–85.
28. Romano A, Lopez ET, Liparoti M, Polverino A, Minino R, Trojsi F, et al. The progressive loss of brain network fingerprints in Amyotrophic Lateral Sclerosis predicts clinical impairment. NeuroImage Clin. 2022;35:103095.
29. Thakore NJ, Lapin BR, Kinzy TG, Pioro EP. Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach. Amyotroph Lateral Scler Front Degener. 2018;19(7–8):483–94.
30. Fang T, Al Khleifat A, Meurgey JH, Jones A, Leigh PN, Bensimon G, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol [Internet]. 2018 May 1 [cited 2023 Sep 6];17(5):416–22. Available from: http://www.thelancet.com/article/S1474442218300541/fulltext
31. De Jongh AD, Van Eijk RPA, Van Den Berg LH. Evidence for a multimodal effect of riluzole in patients with ALS? J Neurol Neurosurg Psychiatry. 2019;1–2.
32. Tramacere I, Dalla Bella E, Chiò A, Mora G, Filippini G, Lauria G. The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2015;86(11):1180–5.
33. Chiò A, Hammond ER, Mora G, Bonito V, Filippini G. Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry [Internet]. 2015 Jan 1 [cited 2023 Sep 6];86(1):38–44. Available from: https://jnnp.bmj.com/content/86/1/38
34. Jones AR, Jivraj N, Balendra R, Murphy C, Kelly J, Thornhill M, et al. Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Front Degener. 2014;15(3–4):285–91.
35. Balendra R, Al Khleifat A, Fang T, Al-Chalabi A. A standard operating procedure for King’s ALS clinical staging. Amyotroph Lateral Scler Front Degener. 2019;20(3–4):159–64.
Article Sidebar
Published
Mar 18, 2024
Article Details
How to Cite
Dr. Mohammed A Maeshi , Dr. Fahad A Majrabi , Dr. Ahlam M Muharraq , Dr. Walaa S Areeshi , Abdulrahman H Alotibi , Dr. GHAIDA Y Alsuhaym , D. T. H. A. , D. A. S. A. , D. M. A. H. , . D. Y. M. A. , D. R. A. A. , D. A. H. M. , . D. I. M. S. , D. K. M. kulaybi , D. A. A. A. B. ,. (2024). The ability of King’s clinical staging and Milano-Torino (MiToS) functional staging in the prediction of amyotrophic lateral sclerosis (ALS) progression: A meta-analysis study. Journal of Population Therapeutics and Clinical Pharmacology, 31(3), 1315-1336. https://doi.org/10.53555/jptcp.v31i3.5163
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Dr. Mohammed A Maeshi , Dr. Fahad A Majrabi , Dr. Ahlam M Muharraq , Dr. Walaa S Areeshi , Abdulrahman H Alotibi , Dr. GHAIDA Y Alsuhaym , D. T. H. A. , D. A. S. A. , D. M. A. H. , . D. Y. M. A. , D. R. A. A. , D. A. H. M. , . D. I. M. S. , D. K. M. kulaybi , D. A. A. A. B. ,. (2024). The ability of King’s clinical staging and Milano-Torino (MiToS) functional staging in the prediction of amyotrophic lateral sclerosis (ALS) progression: A meta-analysis study. Journal of Population Therapeutics and Clinical Pharmacology, 31(3), 1315-1336. https://doi.org/10.53555/jptcp.v31i3.5163